- Home
- ETON vs FCO Comparison
ETON vs FCO Comparison
Compare ETON & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- FCO
- Stock Information
- Founded
- ETON 2017
- FCO 1991
- Country
- ETON United States
- FCO United Kingdom
- Employees
- ETON N/A
- FCO N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- FCO Investment Managers
- Sector
- ETON Health Care
- FCO Finance
- Exchange
- ETON Nasdaq
- FCO Nasdaq
- Market Cap
- ETON 388.3M
- FCO 85.6M
- IPO Year
- ETON 2018
- FCO N/A
- Fundamental
- Price
- ETON $14.85
- FCO $6.50
- Analyst Decision
- ETON Strong Buy
- FCO
- Analyst Count
- ETON 3
- FCO 0
- Target Price
- ETON $29.67
- FCO N/A
- AVG Volume (30 Days)
- ETON 636.4K
- FCO 100.1K
- Earning Date
- ETON 08-07-2025
- FCO 01-01-0001
- Dividend Yield
- ETON N/A
- FCO 14.96%
- EPS Growth
- ETON N/A
- FCO N/A
- EPS
- ETON N/A
- FCO 0.43
- Revenue
- ETON $48,327,000.00
- FCO N/A
- Revenue This Year
- ETON $103.21
- FCO N/A
- Revenue Next Year
- ETON $51.34
- FCO N/A
- P/E Ratio
- ETON N/A
- FCO $12.30
- Revenue Growth
- ETON 40.88
- FCO N/A
- 52 Week Low
- ETON $3.25
- FCO $4.73
- 52 Week High
- ETON $21.48
- FCO $6.63
- Technical
- Relative Strength Index (RSI)
- ETON 54.31
- FCO 65.74
- Support Level
- ETON $13.78
- FCO $6.42
- Resistance Level
- ETON $16.27
- FCO $6.59
- Average True Range (ATR)
- ETON 0.83
- FCO 0.09
- MACD
- ETON 0.32
- FCO 0.01
- Stochastic Oscillator
- ETON 77.67
- FCO 79.07
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.